Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy

References

• Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand.80, 428–435 (1991).
   PubMed Web of Science ®Google Scholar
• Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch. Dis. Child.27, 519–525 (1952).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol.22(11), 633–640 (2001).
   PubMed Web of Science ®Google Scholar
• Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol.254(2), 149–154 (2009).
   PubMed Web of Science ®Google Scholar
• Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J. Immunol.180(12), 7785–7791 (2008).
   PubMed Web of Science ®Google Scholar
• Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol.17, 189–220 (1999).
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Gundle R, Davies RJ et al. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a recipricol program of activation. J. Immunol.173(10), 6418–6426 (2004).
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune respose. Nature449(7164), 819–826 (2007).
   PubMed Web of Science ®Google Scholar
• Badovinac VP, Harty JT. CD8+ T-cell homeostasis after infection: setting the ‘curve’. Microbes Infect.4, 441–447 (2002).
   PubMedGoogle Scholar
• de Saint Basile G, Fischer A. Defective cytotoxic granule-mediated cell death pathway impairs T lymphocyte homeostasis. Curr. Opin. Rheumatol.15, 436–445 (2003).
   PubMed Web of Science ®Google Scholar
• Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann. Med.38, 20–31 (2006).
   PubMed Web of Science ®Google Scholar
• Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of perforin upregulation in human CD8 T cells. Cytometry A73(11), 1050–1057 (2008).
   PubMedGoogle Scholar
• Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu. Rev. Cell. Dev. Biol.23, 495–517 (2007).
   PubMed Web of Science ®Google Scholar
• Neeft M, Weiffer M, de Jong AS et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol. Biol. Cell16(2), 731–741 (2005).
   PubMed Web of Science ®Google Scholar
• Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell. Mol. Life Sci.65(18), 2801–2813 (2008).
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods281(1–2), 65–78 (2003).
   PubMed Web of Science ®Google Scholar
• Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr. Opin. Allergy Clin. Immunol.6, 410–415 (2006).
   PubMedGoogle Scholar
• Grossman WJ, Verbsky JW, Tollefsen BL et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood104(9), 2842–2848 (2004).
   Google Scholar
• Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr. Opin. Immunol.19(3), 301–308 (2007).
   PubMed Web of Science ®Google Scholar
• Liu C, Walsh CM, Young JD. Perforin: structure and function. Immunol. Today16, 194–201 (1995).
   PubMedGoogle Scholar
• Urrea Moreo R, Gil J, Rodriguez-Sainz C et al. Functional assessment of perforin C2 domain mutations illustrates the critical role for calcium-dependent binding in perforin cytotoxic function. Blood113(2), 338–346 (2009).
   PubMedGoogle Scholar
• Pinkoski MJ, Green DR. Lymphocyte apoptosis: refining the paths to perdition. Curr. Opin. Hematol.9, 43–49 (2002).
   PubMedGoogle Scholar
• Metkar SS, Wang B, Aguilar-Santelises M et al. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity16, 417–428 (2002).
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol.6, 940–952 (2006).
   PubMed Web of Science ®Google Scholar
• Palm-Apergi C, Lorents A, Padari K, Pooga M, Hallbrink M. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J.23(1), 214–223 (2009).
   PubMed Web of Science ®Google Scholar
• Keefe K, Shi L, Feske S et al. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity23(3), 249–262 (2005).
   PubMedGoogle Scholar
• Bots M, Medema JP. Granzymes at a glance. J. Cell Sci.119, 5011–5014 (2006).
   PubMed Web of Science ®Google Scholar
• Fellows E, Gil-Parrado S, Jenne DE, Kurschus FC. Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood110(2), 544–552 (2007).
   PubMedGoogle Scholar
• Bratke K, Kuepper M, Bade B, Virchow JC, Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol.35(9), 2608–2616 (2005).
   PubMed Web of Science ®Google Scholar
• Snoeck HW, Van Bockstaele DR, Nys G et al. Interferon γ selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells. J. Exp. Med.180(3), 1177–1182 (1994).
   PubMedGoogle Scholar
• Zeerleder S, Hack CE, Caliezi C et al. Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction. Clin. Immunol.116(2), 158–165 (2005).
   PubMed Web of Science ®Google Scholar
• Sato T, Seller C, Young NS, Maciejeskwi JP. Hematopoietic inhibition by interferon-γ is partially mediated through interferon regulatory factor-1. Blood86(9), 3373–3380 (1995).
   PubMed Web of Science ®Google Scholar
• Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon g are essential for the disorder. Blood104, 735–743 (2004).
   PubMed Web of Science ®Google Scholar
• Osugi Y, Hara J, Tagawa S et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood89(11), 4100–4103 (1997).
   PubMed Web of Science ®Google Scholar
• Marcenaro S, Gallo F, Martini S et al. Analysis of natural killer-cell function in familial hemphagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood108, 2316–2323 (2006).
   PubMedGoogle Scholar
• Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on livery biopsy illustrating the key role of activated, IFN-γ-producing lymphocytes and IL-6- and TNF-α-producing macrophages. Blood105(4), 1648–1651 (2005).
   PubMed Web of Science ®Google Scholar
• Haddad E, Sulis ML, Jabado N et al. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood89(3), 794–800 (1997).
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hibi S, Sako M et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparitive study of 9 familial and 14 familial inheritance-unproven cases. J. Pediatr. Hematol. Oncol.20(3), 207–214 (1998).
   PubMedGoogle Scholar
• Schneider EM, Lorenz I, Muller-Rosenberger M et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood89, 4100–4103 (2002).
   Google Scholar
• Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels of interferon-γ, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Leuk. Lymphoma3, 287 (1991).
   PubMed Web of Science ®Google Scholar
• Henter JI, Elinder G, Soder O et al. Hypercytokinemia in familial hemophagocytosis. Blood78, 2918–2922 (1991).
   PubMed Web of Science ®Google Scholar
• Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am. J. Pedatr. Hematol. Oncol.15, 92–98 (1993).
   PubMedGoogle Scholar
• Ohga S, Matsuzaki A, Nishizaki M et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome: interferon-γ as a sensitive indicator of disease activity. Am. J. Pedatr. Hematol. Oncol.15, 291–298 (1993).
   PubMedGoogle Scholar
• Akashi K, Hayashi S, Gondo H et al. Involvement of interferon-γ and macrophage colony-stimulating factor in pathogenesis of hemophagocytic lymphohistiocytosis in adults. Br. J. Haematol.87, 243–250 (1994).
   PubMed Web of Science ®Google Scholar
• Tamura K, Kanazawa T, Tsukada S et al. Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer51(5), 662–668 (2008).
   PubMed Web of Science ®Google Scholar
• van Dommelen SLH, Sumaria N, Schreiber RD et al. Perforin and granzyme have distinct roles in defensive immunity and immunopathology. Immunity25, 835–848 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first-degree relatives. Pediatr. Res.44, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Schneider EM, Lorenz I, Walther P, Janka GE. Natural killer deficiency: a minor or major factor in the manifestation of hemophagocytic lymphohistiocytosis? J. Pediatr. Hematol. Oncol.25(9), 680–683 (2003).
   PubMedGoogle Scholar
• Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun. Rev.3, 69–75 (2004).
   PubMed Web of Science ®Google Scholar
• Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8+ T cells after infection. Nat. Immunol.3(7), 619–626 (2002).
   PubMed Web of Science ®Google Scholar
• Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. Nat. Immunol.5(8), 809–817 (2004).
   PubMed Web of Science ®Google Scholar
• Andrews DM, Andoniou CD, Fleming P, Smyth MJ, Degli-Esposti MA. The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or g interferon. J. Virol.82, 4931–4937 (2008).
   PubMedGoogle Scholar
• Kagi D, Odermatt B, Mak TW. Homeostatic regulation of CD8+ T cells by perforin. Eur. J. Immunol.29, 3262–3272 (1999).
   PubMed Web of Science ®Google Scholar
• Ohadi M, Lalloz MRA, Sham P et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am. J. Hum. Genet.64, 165–171 (1999).
   PubMed Web of Science ®Google Scholar
• Stepp SE, Dufourcq-Lagelouse R, Le Deist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science286, 1957–1959 (1999).
   PubMed Web of Science ®Google Scholar
• Kogawa K, Lee SM, Villanueva J et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood99(1), 61–66 (2002).
   PubMed Web of Science ®Google Scholar
• Ueda I, Morimoto A, Inaba T et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br. J. Haematol.121, 503–510 (2003).
   PubMed Web of Science ®Google Scholar
• Molleran Lee S, Villanueva J, Sumegi J et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J. Med. Genet.41(2), 137–144 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol.3, 361–370 (2003).
   PubMed Web of Science ®Google Scholar
• Molleran Lee S, Sumegi J, Villanueva J et al. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50DELT mutation. J. Pediatr.149, 134–137 (2006).
   PubMedGoogle Scholar
• Clementi R, Zur Stadt U, Savoldi G et al. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J. Med. Genet.38, 643–646 (2001).
   PubMedGoogle Scholar
• Trizzino A, Zur Stadt U, Risma K et al. Genotype phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J. Med. Genet.45, 15–21 (2008).
   PubMedGoogle Scholar
• Voskoboinik I, Sutton VR, Ciccone A et al. Perforin activity and immune homeostasis: the common A91V polymorphisim in perforin results in both presynaptic and postsynaptic defects in function. Blood110(4), 1184–1190 (2007).
   PubMedGoogle Scholar
• Zhang K, Johnson JA, Biroschak J et al. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. Int. J. Immunogenet.34(4), 231–233 (2007).
   PubMedGoogle Scholar
• Dufourcq-Lagelouse R, Jabado N, Le Deist F et al. Linkage of familial hemophagocytic lymphhistiocytosis to 10q21–22 and evidence for heterogeneity. Am. J. Hum. Genet.64, 172–179 (1999).
   PubMed Web of Science ®Google Scholar
• Graham GE, Graham LM, Bridge PJ et al. Further evidence for genetic heterogeneity in familial hemophagocytic lymphohistiocytosis (FHLH). Pediatr. Res.48(2), 227–232 (2000).
   PubMed Web of Science ®Google Scholar
• Feldmann J, Callebaut I, Raposo G et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell115, 461–473 (2003).
   PubMed Web of Science ®Google Scholar
• Pivot-Pajot C, Varoqueaux F, De Saint Basile G, Bourgain SG. Munc13-4 regulates granule secretion in human neutrophils. J. Immunol.180(10), 6786–6797 (2008).
   PubMedGoogle Scholar
• Menasche G, Pastural E, Feldmann J et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet.25(2), 173–176 (2000).
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S et al. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. Crit. Rev. Oncol. Hematol.53, 209–223 (2005).
   PubMed Web of Science ®Google Scholar
• Santoro A, Cannella S, Trizzino A et al. Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica93, 1086–1090 (2008).
   PubMedGoogle Scholar
• Rudd E, Bryceson YT, Zheng C et al. Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J. Med. Genet.45(3), 134–141 (2008).
   PubMedGoogle Scholar
• Ueda I, Ishii E, Morimoto A et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pedatr. Blood Cancer46, 482–488 (2006).
   PubMedGoogle Scholar
• Zur Stadt U, Beutel K, Kolberg S et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11 and RAB27A. Hum. Mutat.27(1), 62–68 (2006).
   PubMed Web of Science ®Google Scholar
• Bryceson YT, Rudd E, Zheng C et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagoctic lymphohistiocytosis 4 (FHL4) patients. Blood110(6), 1906–1915 (2007).
   PubMed Web of Science ®Google Scholar
• Crozat K, Hoebe K, Ugolini S et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med.204(4), 853–863 (2007).
   PubMed Web of Science ®Google Scholar
• Zur Stadt U, Schmidt S, Kasper B et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Gen.14(6), 827–834 (2005).
   PubMed Web of Science ®Google Scholar
• Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am. Soc. Hematol. Educ. Program82–88 (2005).
   PubMedGoogle Scholar
• Yamamoto K, Ishii E, Horiuchi H et al. Mutations of syntaxin 11 and SNAP23 genes as causes of familial hemophagocytic lymphohistiocytosis were not found in Japanese people. J. Hum. Genet.50, 600–603 (2005).
   PubMedGoogle Scholar
• Arenson LN, Brickshawana A, Segovis CM et al. Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J. Immunol.179(6), 3397–3401 (2007).
   PubMedGoogle Scholar
• Kaplan J, De Domenico I, McVey Ward D. Chediak–Higashi syndrome. Curr. Opin. Hematol.15, 22–29 (2008).
   PubMed Web of Science ®Google Scholar
• Enders A, Zieger B, Schwarz K et al. Lethal hemphagocytic lymphohistiocytosis in Hermansky–Pudlak syndrome type II. Blood108, 81–87 (2006).
   PubMedGoogle Scholar
• Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat. Rev. Immunol.3, 813–821 (2003).
   PubMed Web of Science ®Google Scholar
• Grunebaum E, Zhang J, Dadi H, Roifman CM. Haemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br. J. Haematol.108, 834–837 (2000).
   PubMed Web of Science ®Google Scholar
• Schultz KAP, Neglia JP, Smith AR et al. Familial hemophagocytic lymphohistiocytosis in two brothers with X-linked agammaglobulinemia. Pediatr. Blood Cancer51, 293–295 (2008).
   PubMedGoogle Scholar
• Stinchcombe J, Bossi G, Griffiths G. Linking albinism and immunity: the secrets of secretory lysosomes. Science305(5680), 55–59 (2004).
   PubMed Web of Science ®Google Scholar
• Schmid JP, Ho C, Diana J et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur. J. Immunol.38, 3219–3225 (2008).
   PubMedGoogle Scholar
• Stinchcombe J, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity15(5), 751–761 (2001).
   PubMed Web of Science ®Google Scholar
• Nagle DL, Karim MA, Woolf EA et al. Identification and mutation analysis of the complete gene for Chediak–Higashi syndrome. Nat. Genet.14(3), 307–311 (1996).
   PubMed Web of Science ®Google Scholar
• Fontana S, Parolini S, Vermi W et al. Innate immunity defects in Hermansky–Pudlak type 2 syndrome. Blood107(12), 4857–4864 (2006).
   PubMed Web of Science ®Google Scholar
• Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol.25, 337–379 (2007).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Villanueva J, Lee SM et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood105(8), 3066–3071 (2005).
   PubMedGoogle Scholar
• Rigaud S, Fondaneche MC, Lambert N et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature444(7115), 110–114 (2006).
   PubMed Web of Science ®Google Scholar
• Janka GE. Familial erythrophagocytic lymphohistiocytosis. Eur. J. Pediatr.140, 221–230 (1983).
   PubMed Web of Science ®Google Scholar
• Arico M, Janka G, Fischer A et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. Leukemia10, 197–203 (1996).
   PubMed Web of Science ®Google Scholar
• Hirst WJ, Layton DM, Singh S, Mieli-Vergani G, Chessells JM. Haemophagocytic lymphohistiocytosis: experience at two U.K. centres. Br. J. Haematol.88, 731–739 (1994).
   PubMed Web of Science ®Google Scholar
• Morrell DS, Pepping MA, Scott P, Esterly NB, Drolet BA. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch. Dermatol.138, 1208–1212 (2002).
   PubMedGoogle Scholar
• Horne A, Trottestam H, Arico M et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br. J. Haematol.140, 327–335 (2007).
   PubMed Web of Science ®Google Scholar
• Stapp J, Wilkerson S, Stewart D et al. Fulminant neonatal liver failure in siblings: probably congenital hemophagocytic lymphohistiocytosis. Pediatr. Dev. Pathol.9(3), 239–244 (2006).
   PubMedGoogle Scholar
• Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin. Oncol.28, 342–347 (1991).
   Google Scholar
• Gupta A, Tyrrell P, Valani R et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer51, 402–404 (2008).
   PubMed Web of Science ®Google Scholar
• Goo HW, Weon YC. A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis. Pediatr. Radiol.37, 1110–1117 (2007).
   PubMedGoogle Scholar
• Kataoka Y, Todo S, Morioka Y et al. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis. Cancer65, 1937–1941 (1990).
   PubMedGoogle Scholar
• Perez N, Virelizier J, Arenzana-Seisdedos F, Fischer A, Griscelli C. Impaired natural killer cell activity in lymphohistiocytosis syndrome. J. Pediatr. Hematol. Oncol.104, 569–573 (1984).
   Google Scholar
• Eife R, Janke GE, Belohrasky BH. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr. Hematol. Oncol.6, 265–272 (1989).
   PubMed Web of Science ®Google Scholar
• Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of hemophagocytic lymphohistiocytosis. Br. J. Haematol.114, 761–769 (1991).
   Google Scholar
• Filipovich A. Hemophagocytic lymphohistiocytosis. Immunol. Allergy Clin. N. Am.22, 281–300 (2002).
   Web of Science ®Google Scholar
• Janka G, Muller-Rosenberger M, Schneider EM. Persistent defect of cellular cytotoxicity after Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Blood96, 36b (2001).
   Google Scholar
• Janka G, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br. J. Haematol.124, 4–14 (2004).
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer48, 124–131 (2007).
   PubMed Web of Science ®Google Scholar
• Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin. Infect. Dis.36, 306–312 (2003).
   PubMed Web of Science ®Google Scholar
• Castillo L. High elevated ferritin levels and the diagnosis of HLH/Sepsis/SIRS/MODS/MAS. Pediatr. Blood Cancer51, 710–711 (2008).
   PubMedGoogle Scholar
• Suster S, Hilsenbeck S, Rywlin AM. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum. Pathol.19, 705–712 (1988).
   PubMed Web of Science ®Google Scholar
• Strauss R, Neureiter D, Westenburger B et al. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients – a postmortem clinicopathologic analysis. Crit. Care Med.32(6), 1316–1321 (2004).
   PubMed Web of Science ®Google Scholar
• Gauvin F, Toledano B, Champagne J, Lacroix J. Reactive hemophagocytic syndrome presenting as a component of multiple organ dysfunction syndrome. Crit. Care Med.28(9), 3341–3345 (2000).
   PubMed Web of Science ®Google Scholar
• Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer50, 1227–1235 (2008).
   PubMed Web of Science ®Google Scholar
• Kapoor S. Distinguishing hemophagocytic lymphohistiocytosis from hemochromatosis in patients with hyperferritinemia. Pediatr. Blood Cancer50, 1287–1297 (2008).
   PubMedGoogle Scholar
• Allen CE, McClain KL, Filipovich L. Highly elevated ferritin levels and the diagnosis of HLH/sepsis/SIRS/MODS/MAS – response. Pediatr. Blood Cancer51, 711 (2008).
   Google Scholar
• Emminger W, Zlabinger GJ, Fritsch G, Urbanek R. CD14dim/CD16bright monocytes in hemophagocytic lymphohistiocytosis. Eur. J. Immunol.31, 1716–1719 (2001).
   PubMedGoogle Scholar
• Schaer DJ, Schleiffenbaum B, Kurrer M et al. Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Hematol.74, 6–10 (2005).
   PubMed Web of Science ®Google Scholar
• Moller HJ, Moestrup SK, Weis N et al. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit. Care Med.34(10), 2561–2566 (2006).
   PubMed Web of Science ®Google Scholar
• Bleesing J, Prada A, Siegel DM et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and unrelated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum.56(3), 965–971 (2007).
   PubMed Web of Science ®Google Scholar
• Moller HJ, Gronbaek H, Schiodt FV et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J. Hepatol.47(5), 671–676 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int. J. Hematol.86, 58–65 (2007).
   PubMed Web of Science ®Google Scholar
• Allen M, De Fusco C, Legrand F et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica86, 499–503 (2001).
   PubMedGoogle Scholar
• Nagafuji K, Nonami A, Kumano T et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica92, 978–981 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. BMT42, 433–437 (2008).
   Google Scholar
• Risdall RJ, McKenna RW, Nesbit ME et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer44(3), 993–1002 (1979).
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Talati NJ, Vaughan C et al. Infections associated with haemophagocytic syndrome. Lancet Infect. Dis.7, 814–822 (2007).
   PubMed Web of Science ®Google Scholar
• Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet367(9513), 870–873 (2006).
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Yachie A. Cell type specific infection of Epstein–Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit. Rev. Oncol. Hematol.44, 283–294 (2002).
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Yachie A, Takei K et al. Differential cellular targets of Epstein–Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood98, 1882–1888 (2001).
   PubMed Web of Science ®Google Scholar
• Imashuku S. Systemic type Epstein–Barr virus-related lymphoproliferative diseases in children and young adults: challenges for pediatric hemato-oncologists and infectious disease specialists. Pediatr. Hematol. Oncol.24, 563–568 (2007).
   PubMed Web of Science ®Google Scholar
• Chuang HC, Lay JD, Hsieh WC et al. Epstein–Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood106(9), 3090–3096 (2005).
   PubMed Web of Science ®Google Scholar
• Wada T, Kurokawa T, Toma T et al. Immunophenotypic analysis of Epstein–Barr virus (EBV)-infected CD8+ T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur. J. Hematol.79, 72–75 (2007).
   PubMed Web of Science ®Google Scholar
• Beutel K, Janka GE, Schneider ME. EBV-associated hemophagocytic lymphohistiocytosis (HLH) in German children. Med. Pediatr. Oncol.38, 224 (2002).
   Google Scholar
• Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. North Am.12, 435–444 (1998).
   PubMed Web of Science ®Google Scholar
• O’Brien MM, Lee-Kim Y, George YI et al. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer50(2), 381–383 (2008).
   PubMedGoogle Scholar
• Kuzmanovic M, Rasovic N, Micic D et al. Epstein–Barr virus associated hemophagocytic lymphohistiocytosis during maintenance treatment of acute lymphoblastic leukemia. Pediatr. Blood Cancer46(7), 832 (2006).
   PubMedGoogle Scholar
• Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child.85(5), 421–426 (2001).
   PubMed Web of Science ®Google Scholar
• Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatr.148(5), 683–686 (2006).
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Schneider R. Macrophage activating syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol.30, 401–403 (2003).
   PubMed Web of Science ®Google Scholar
• Stephan JL, Kone-Paut I, Galambrun C et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology40, 1285–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr. Opin. Rheumatol.15, 587–590 (2003).
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Schneider R. Macrophage activation syndrome – what’s in a name! J. Rheumatol.30(12), 2513–2516 (2003).
   PubMedGoogle Scholar
• Grom AA, Villanueva J, Lee S et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr.142, 292–296 (2003).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Lee S, Giannini EH et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis. Res. Ther.7, R30–R37 (2005).
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol.34(5), 1133–1138 (2007).
   PubMed Web of Science ®Google Scholar
• Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun. Rev.7, 305–308 (2008).
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology44, 1350–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Donn R, Ellison S, Lamb R et al. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum.58(3), 869–874 (2008).
   PubMedGoogle Scholar
• Hazen MM, Woodward AL, Hofmann I et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum.58(2), 567–570 (2008).
   PubMed Web of Science ®Google Scholar
• Ravelli A, Magni-Manzoni S, Pistorio A et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr.146, 598–604 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol.19, 477–481 (2007).
   PubMed Web of Science ®Google Scholar
• Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med. Pediatr. Oncol.38, 305–309 (2002).
   PubMedGoogle Scholar
• Ambruso DR, Hays T, Zwartjes WJ, Tubergen DG, Favara BE. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213. Cancer45, 2516–2520 (1980).
   PubMed Web of Science ®Google Scholar
• Fischer A, Virelizier J, Arenzana-Seisdedos F et al. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophphyllotoxin, steroids, intrathecal methotrexate and cranial irradiation. Pediatrics76, 263–268 (1985).
   PubMed Web of Science ®Google Scholar
• Stephan JL, Donadieu J, Le Deist F et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids and cyclosporin A. Blood82, 2319–2323 (1993).
   PubMed Web of Science ®Google Scholar
• Fischer A, Cerf-Bensussan N, Blanche S et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J. Pediatr.108(2), 267–270 (1986).
   PubMed Web of Science ®Google Scholar
• Caselli D, Aricò M; EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant41, S8–S13 (2008).
   PubMedGoogle Scholar
• Henter JI, Samuelsson-Horne A, Arico M et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood100, 2367–2373 (2002).
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Imashuku S, Henter JI, Sullivan KE. Healing hemophagocytosis. Clin. Immunol.117, 121–124 (2005).
   PubMedGoogle Scholar
• Imashuku S, Kuriyama K, Sakai R et al. Treatment of Epstein–Barr virus-associated hemophagocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med. Pediatr. Oncol.41(2), 103–109 (2003).
   PubMedGoogle Scholar
• Mahlaoui N, Ouachee-Chardin M, de Saint Basile G et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymoctye globulins: a single-center retrospective report of 38 patients. Pediatrics120(3), e622–e628 (2007).
   PubMed Web of Science ®Google Scholar
• Imashuku S. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer48, 121–123 (2007).
   PubMedGoogle Scholar
• Imashuku S, Kuriyama K, Teramura T et al. Requirement for etoposide in the treatment of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. J. Clin. Oncol.19(10), 2665–2673 (2001).
   PubMed Web of Science ®Google Scholar
• Trottestam H, Beutel K, Meeths M et al. Treatment of then X-linked lymphoproliferative, Griscelli and Chediak–Higashi syndromes by HLH directed therapy. Pediatr. Blood Cancer52(2), 268–272 (2009).
   PubMedGoogle Scholar
• Imashuku S, Teramura T, Tauchi H et al. Longitudinal follow-up of patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica89, 183–188 (2004).
   PubMed Web of Science ®Google Scholar
• Baker KS, Filipovich AH, Gross TG et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. BMT42, 175–180 (2008).
   Google Scholar
• Ouachee-Chardin M, Elie C, de Saint Basile G et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics117(4), e743–e750 (2006).
   PubMed Web of Science ®Google Scholar
• Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell tranplantation in childhood malignant and nonmalignant disease. BMT41(2), 173–182 (2008).
   Google Scholar
• Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood107(3), 1233–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Chen R, Lin K, Lin D et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br. J. Haematol.89, 282–290 (1995).
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hibi S, Ohara T et al. Effective control of Epstein–Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood93, 1869–1874 (1999).
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hibi S, Kuriyama K et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein–Barr virus-related hemophagocytic lymphohistiocytosis. Leuk. Lymphoma36(3–4), 339–346 (2000).
   PubMed Web of Science ®Google Scholar
• Perel Y, Alos N, Ansoborlo A, Carrere A, Guillard J-M. Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome. Acta Paediatr.86, 911 (1997).
   PubMed Web of Science ®Google Scholar
• Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol.29, 569–573 (2007).
   PubMed Web of Science ®Google Scholar
• Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activating syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J. Pediatr.128, 275–278 (1996).
   PubMed Web of Science ®Google Scholar
• Tristano AG, Casanova-Escalona L, Torres A, Rodriguez MA. Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J. Clin. Rheumatol.9(4), 253–258 (2003).
   PubMed Web of Science ®Google Scholar
• Makay B, Yilmaz S, Turkyilmaz Z et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr. Blood Cancer50, 419–421 (2008).
   PubMed Web of Science ®Google Scholar
• Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J. Rheumatol.28(9), 2120–2124 (2001).
   PubMed Web of Science ®Google Scholar
• Sawar H, Espinoza RL, Gedalia A. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis. J. Rheumatol.31, 623 (2004).
   PubMedGoogle Scholar
• Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol.4, 615–620 (2008).
   PubMedGoogle Scholar
• Sung L, Weitzman S, Petric M, King SM. The role of infections in primary hemophagocytic lymphohistiocytosis: a case series and review of the literature. Clin. Infect. Dis.33(10), 1644–1648 (2001).
   PubMedGoogle Scholar
• Imashuku S, Teramura T, Morimoto A, Hibi S. Recent developments in the management of haemophagocytic lymphohistiocytosis. Expert Opin. Pharmacother.2, 1437–1448 (2001).
   PubMedGoogle Scholar
• Henzan T, Nagafuji K, Tsukamoto H et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am. J. Hematol.81, 59–61 (2006).
   PubMed Web of Science ®Google Scholar
• Olin RL, Nichols KE, Naghashpour M et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am. J. Hematol.83, 747–749 (2008).
   PubMed Web of Science ®Google Scholar